BTX-A safe and effective treatment option for bruxism and masseter hypertrophy

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-07-23 14:30 GMT   |   Update On 2023-07-23 15:11 GMT
Advertisement

BTX-A safe and effective treatment option for bruxism and masseter hypertrophy suggests a new study published in the Journal of Cranio-Maxillofacial Surgery.

This study aims to confirm the effectiveness and safety of a prabotulinumtoxin type A (praBTX-A) injection in patients with bruxism and masseter hypertrophy. The study included patients who ground or clenched their teeth while sleeping and had computed tomography (CT) scans that showed a maximum thickness of the masseter muscle of 15 mm or more. The praBTX-A was administered bilaterally into the masseter muscles; 15 U/side for group 1, 25 U/side for group 2, and 35 U/side for group 3. CT scans and bruxism questionnaires were conducted before and eight weeks after the injection. Thirty-seven patients were enrolled, but three dropped out due to loss of follow-up. After injection, masseter thickness decreased to 15.1 ± 2.0 mm for group 1, 14.3 ± 2.9 mm for group 2, and 13.4 ± 1.8 mm for group 3 (p = 0.043). Group 3 showed a statistically significant lower masseter thickness compared to group 1 (p = 0.039). Both subjective and objective frequencies of bruxism decreased for all groups, but there were no significant differences in either subjective (p = 0.396) or objective frequencies (p = 0.87) between the groups after the injection. The results of this study suggest that praBTX-A injection is a safe and effective treatment for bruxism and masseter hypertrophy. A dosage of 35 IU/side can effectively decrease masseter thickness and relieve bruxism symptoms. Even the minimum dosage of 15 IU/side can contribute to improvements in bruxism symptoms. This investigation provides valuable information for managing bruxism that is associated with hypertrophic masseter muscles.

Reference:

Bok Ki Jung, Hojin Park, Young Woo Cheon, In Sik Yun, Jong-Woo Choi, Han Jo Kim, Mu Young Lee, Byeong Su Kang, Tae Jo Kang, Clinical investigation of botulinum toxin (prabotulinumtoxin A) for bruxism related to masseter muscle hypertrophy: A prospective study, Journal of Cranio-Maxillofacial Surgery, Volume 51, Issue 5, 2023, Pages 332-337,

ISSN 1010-5182, https://doi.org/10.1016/j.jcms.2023.05.005.

Keywords:

BTX-A, safe, effective, treatment, option, bruxism, masseter, hypertrophy, Botulinum toxins; Bruxism; Masseter muscle, Bok Ki Jung, Hojin Park, Young Woo Cheon, In Sik Yun, Jong-Woo Choi, Han Jo Kim, Mu Young Lee, Byeong Su Kang, Tae Jo Kang, Journal of Cranio-Maxillofacial Surgery


Tags:    
Article Source : Journal of Cranio-Maxillofacial Surgery

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News